Fig. 3: Bmi-1 is required for LSD1-driven HNSCC oncogenesis. | Cell Death & Disease

Fig. 3: Bmi-1 is required for LSD1-driven HNSCC oncogenesis.

From: Targeting LSD1 suppresses stem cell-like properties and sensitizes head and neck squamous cell carcinoma to PD-1 blockade

Fig. 3: Bmi-1 is required for LSD1-driven HNSCC oncogenesis.The alternative text for this image may have been generated using AI.

A The correlations between the expression levels of LSD1 and Bmi-1 in HNSCC. B Western blot analysis of LSD1, Bmi-1, and Sox2 expression in the control and LSD1-silenced groups of HN12 and HN30 cells. C Western blot analysis of LSD1, Bmi-1, and Sox2 expression in the control and LSD1-overexpressing groups of HN13 and CAL27 cells. D Western blot analysis of LSD1 and Bmi-1 expression in the control, LSD1-silenced, and Bmi-1-rescued groups of HN30 cells. E, F Representative images and quantitative analysis of a sphere-formation assay performed with the control, LSD1-silenced, and Bmi-1 rescued groups of HN30 cells. *P < 0.01, error bar values represent the SD. G The expression of endogenous LSD1 and Bmi-1 in various tumor cell lines was analyzed by western blotting. H Values are normalized to the value of GAPDH. I The expression of LSD1 and Bmi-1 in 14 fresh-frozen human HNSCC tumors was examined by western blotting. J, K Eighty-five HNSCC specimens were immunostained using antibodies against LSD1 and Bmi-1 and control serum (data not shown). Representative images of immunohistochemical (IHC) staining of the same tumor samples are shown in J, and the statistical analysis is shown in K.

Back to article page